Form IRANNOTICE TENARIS SA
Tweet
Share
E-mail |
Tenaris S.A. 26, Boulevard Royal 4th Floor L-2449 LUXEMBOURG R.C.S. Luxembourg B-85.203 |
March 31, 2026
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, DC 20549
|
Re: |
Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended |
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Tenaris S.A. has made disclosures pursuant to such provisions in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission on March 31, 2026.
| Respectfully submitted, | ||
|
|
TENARIS S.A.
|
|
|
|
|
s/ Carlos Gómez Álzaga |
|
|
By |
|
|
|
|
Name: Carlos Gómez Álzaga |
|
|
|
Title: Chief Financial Officer |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CoreAge Rx Achieves High Patient Satisfaction Ratings and Expands Member Support with New Wellness Community
- CoreAge Rx Announces the Launch of a New Flat-Rate GLP-1 Weight Management Programme
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
